CureVac Investors Shape Company's Future in Critical Shareholder Vote

Rhea-AI Filing Summary

CureVac filed a Form 6-K reporting the completion of its annual general meeting of shareholders held on June 26, 2025. The filing primarily serves to notify the submission of voting results from the meeting.

Key Points:

• The company submitted final tabulation of shareholder votes from its annual general meeting
• Document was signed by CEO Alexander Zehnder
• Filing includes Exhibit 99.1 containing the detailed voting results
• Company confirms it files annual reports under Form 20-F

The filing is purely administrative in nature, serving as a notice of foreign private issuer. The information provided in this Form 6-K is not deemed "filed" under Section 18 of the Securities Exchange Act and does not carry the associated liabilities or incorporation by reference under the Securities Act of 1933 or Exchange Act.

Form 6-K: How Foreign Companies Report to the SEC →

 

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of June 2025

 

Commission File Number: 001-39446

 

 

 

CureVac N.V.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Friedrich-Miescher-Strasse 15, 72076

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F x         Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes ¨          No x

 

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes ¨          No x

 

 

 

 

 

 

On June 26, 2025, CureVac N.V. (the “Company”) issued a table containing tabulations of the votes cast at the Company’s annual general meeting of shareholders.

 

The information included in this Form 6-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 	CureVac N.V.
 	(Registrant)
 	 
Date: June 26, 2025	By:	/s/ Alexander Zehnder
 	 	Chief Executive Officer

 

 

 

 

EXHIBIT INDEX

 

EXHIBIT NO.	 	DESCRIPTION
99.1	 	Final Tabulation Table of Votes Cast on the Company’s Annual General Meeting of Shareholders.

 

 

 

FAQ

When did CVAC hold its annual general meeting of shareholders in 2025?

According to the 6-K filing, CureVac N.V. (CVAC) held its annual general meeting of shareholders on or before June 26, 2025, as the company issued the vote tabulation results on that date.

Who is the current CEO of CureVac (CVAC)?

According to the 6-K filing, Alexander Zehnder is the Chief Executive Officer of CureVac N.V., as evidenced by his signature on the document dated June 26, 2025.

What was the purpose of CVAC's June 2025 6-K filing?

The purpose of this 6-K filing was to report the tabulation of votes cast at CureVac's annual general meeting of shareholders, which was included as Exhibit 99.1 to the filing.

Where is CVAC's principal executive office located?

CureVac N.V.'s principal executive office is located at Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany, with phone number +49 7071 9883 0.

Does CVAC file annual reports under Form 20-F or Form 40-F?

According to the filing, CureVac N.V. files its annual reports under Form 20-F, as indicated by the marked checkbox in the document.